- Home
- CIGL vs ENTA Comparison
CIGL vs ENTA Comparison
Compare CIGL & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGL
- ENTA
- Stock Information
- Founded
- CIGL 1997
- ENTA 1995
- Country
- CIGL Singapore
- ENTA United States
- Employees
- CIGL N/A
- ENTA N/A
- Industry
- CIGL Diversified Commercial Services
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- CIGL Consumer Discretionary
- ENTA Health Care
- Exchange
- CIGL Nasdaq
- ENTA Nasdaq
- Market Cap
- CIGL 145.9M
- ENTA 160.3M
- IPO Year
- CIGL 2025
- ENTA 2013
- Fundamental
- Price
- CIGL $22.35
- ENTA $7.89
- Analyst Decision
- CIGL
- ENTA Buy
- Analyst Count
- CIGL 0
- ENTA 4
- Target Price
- CIGL N/A
- ENTA $18.00
- AVG Volume (30 Days)
- CIGL 222.1K
- ENTA 181.3K
- Earning Date
- CIGL 01-01-0001
- ENTA 08-04-2025
- Dividend Yield
- CIGL N/A
- ENTA N/A
- EPS Growth
- CIGL N/A
- ENTA N/A
- EPS
- CIGL N/A
- ENTA N/A
- Revenue
- CIGL $10,490,668.00
- ENTA $64,462,999.00
- Revenue This Year
- CIGL N/A
- ENTA N/A
- Revenue Next Year
- CIGL N/A
- ENTA $0.48
- P/E Ratio
- CIGL N/A
- ENTA N/A
- Revenue Growth
- CIGL N/A
- ENTA N/A
- 52 Week Low
- CIGL $3.63
- ENTA $4.09
- 52 Week High
- CIGL $26.95
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- CIGL N/A
- ENTA 67.33
- Support Level
- CIGL N/A
- ENTA $6.95
- Resistance Level
- CIGL N/A
- ENTA $8.23
- Average True Range (ATR)
- CIGL 0.00
- ENTA 0.40
- MACD
- CIGL 0.00
- ENTA 0.00
- Stochastic Oscillator
- CIGL 0.00
- ENTA 75.11
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.